Meeting
2016 ASCO Annual Meeting
Cyclophosphamide, thalidomide and dexamethasone (CTD) as initial therapy for newly diagnosed multiple myeloma patients.
Authors
Jule Franve Vasquez Chavez
Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
Jule Franve Vasquez Chavez , Rossana Esther Ruiz Mendoza , Karina Mayra Aliaga Llerena , Fernando Valencia , Daniel Enriquez , Victor Palacios , Luis Casanova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 34, 2016 (suppl; abstr 8051)
DOI
10.1200/JCO.2016.34.15_suppl.8051
Abstract #
8051
Poster Bd #
316
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.
First Author: Robert M. Rifkin
Poster
2014 ASCO Annual Meeting
Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs.
First Author: Charlotte Pawlyn
Poster
2013 ASCO Annual Meeting
Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma.
First Author: Preet Paul Singh
Poster
2024 ASCO Annual Meeting
Rapid reduction of free light chains and improvement in renal outcomes in patients with newly diagnosed multiple myeloma admitted with acute kidney injury with daratumumab-based therapy and without plasmapheresis.
First Author: E. Bridget Kim